Dear Ms. Firor:

Please refer to your supplemental new drug application dated June 16, 2005, received June 17, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for EMLA (2.5% lidocaine and 2.5% prilocaine) Cream.

We acknowledge receipt of your correspondence dated December 12, 2005.

This supplemental new drug application provides for changes to the WARNINGS and PRECAUTIONS sections of the approved package insert based on post-marketing safety surveillance information.

We have completed our review of this application, as amended, and it is approved, effective on the date of this letter. As agreed in the correspondence dated December 12, 2005 you will delete the following statement from the PRECAUTIONS: Drug Interactions section of the package insert.

The use of EMLA Cream prior to measles-mumps-rubella or intramuscular diphtheria-pertussis-tetanus-inactivated poliovirus-\textit{Haemophilus influenzae b} or Hepatitis B vaccines was not shown to affect mean antibody titres, rate of seroconversion, or the proportion of patients achieving protective or positive antibody titres post immunization, as compared with placebo treated patients.

The final printed labeling (FPL) must be identical, and include the minor editorial revisions indicated, to the enclosed labeling (text for the package insert). These revisions are terms of the approval of this application.

Please submit an electronic version of the FPL according to the guidance for industry titled \textit{Providing Regulatory Submissions in Electronic Format - NDA}. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "\textit{FPL for approved supplement NDA 19-941/S-017}.” Approval of this submission by FDA is not required before the labeling is used.
If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD  20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kimberly Compton, Regulatory Project Manager, at (301) 796-1191.

Sincerely,

{See appended electronic signature page}

Bob A. Rappaport, M.D.
Director
Division of Anesthesia, Analgesia and Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Bob Rappaport
12/19/2005 10:35:26 AM